



Biotech Daily

Wednesday July 9, 2025

Daily news on ASX-listed biotechnology companies

US President Trump 200% Pharmaceutical Tariff 'Little Impact'

[EDITORIAL: US PRESIDENT DONALD TRUMP PHARMACEUTICAL TARIFFS](#)

Prospective 200 percent tariffs on Australian pharmaceutical exports to be levied by US President Donald Trump are not expected to have a significant impact.

Mr Trump was reported on Australian Broadcasting Corporation Radio saying he would introduce 200 percent tariffs in one year to 18 months.

"We're going to give people about a year, a year and a half, to come in, and after that they're going to be tarified, if they have to bring the pharmaceuticals into the country, the drugs and other things into the country, they're going to be tarified at a very, very high rate like 200 percent," Mr Trump said.

Mr Trump does not face a Presidential election until 2029, but there will be an election in November 2026 for the entire US House of Representatives and one third of the US Senate.

Last year, **CSL** said that \$US7,294 million (\$A11,156.4 million) of its \$US14,800 million revenue, or 49.3 percent, came from the US.

CSL said revenue for the year to June 30, 2024 rose 11.2 percent to a record \$US14,800,000,000 with net profit after tax up 20.4 percent to a record \$US2,642,000,000 (BD: Aug 13, 2024).

Today, a CSL spokesman told Biotech Daily the President's remarks were off-the-cuff "and we still don't have the formal detail".

CSL said it would “continue to monitor the situation, closely”.

The spokesman told Biotech Daily the company had “an extensive network of blood collection centres in the US, a little under 350 [centres] and the bulk of plasma products used in the US are processed at our US manufacturing facility in Kankakee, Illinois”.

“The same with vaccines,” the spokesman said. “The bulk of vaccines sold in the US are produced at our Holly Springs facility in North Carolina,” the spokesman said.

Neuren managing-director Jon Pilcher told Biotech Daily that his company did not “export any product”.

In 2023, Neuren said North America partner Acadia Pharmaceuticals had US approval for Daybue, or trofinetide, for Rett syndrome (BD: Mar 13, 2023).

In May, Neuren said US sales of Daybue by Acadia for the three months to March 31, 2025 were up 11 percent to \$US84.6 million (\$A131 million), compared to the prior period with its royalties for the three months up 17 percent to \$13.5 million (BD: May 8, 2025). Today, Mr Pilcher said: “Acadia has it made by a third party and has years of stockpile in the US, so I don’t envisage any impact.”

“Of course, we are paid as a percentage of sales, so if there was any impact it would not be on us,” Mr Pilcher said.

A spokesman for **Mesoblast** referred Biotech Daily to a previous statement that “Mesoblast believes that its allogeneic cellular products, including Ryoncil and Revascor, will not be subject to the tariffs” (BD: Apr 4, 2025).

“Mesoblast develops allogeneic products based on its proprietary remestemcel-L and rexlemestrocel-L mesenchymal lineage stromal and precursor cell platform technologies,” the company said at that time.

“Its allogeneic cellular products derived from these platforms are manufactured from US donors in the US and designated as US origin products,” Mesoblast said.

Orthocell managing-director Paul Anderson told Biotech Daily that Remplir was not a pharmaceutical product.

“We sit within the medical device category and as a result we see no need to manufacture within the US,” Mr Anderson said.

“All products are manufactured within Australia and have price parity with similar products in the US unlike the pharmaceuticals,” Mr Anderson said.

“So, we are on pretty solid ground,” Mr Anderson said.

LTR Pharma executive chair Lee Rodne told Biotech Daily: “We will manufacture in the US for North American sales so we don't expect to be impacted by the tariffs.”

In March, LTR said it was developing a second vardenafil-based nasal spray for erectile dysfunction, called ‘Roxus’, and the US Food and Drug Administration “broadly endorsed” its Spontan development plans (BD: Mar 26, 2025).

Vardenafil is marketed by Bayer as Levitra for erectile dysfunction.

Starpharma chief executive officer Cheryl Maley told Biotech Daily: “Starpharma does not currently manufacture in the US, and does not foresee any impact at this stage.”

Acrux managing-director John Warmbrunn told Biotech Daily: “We are in the fortunate position that all our current income generating products are sourced from the US”.

“Some other partners have well-developed plans for reshoring to the US, so we believe we are covered,” Mr Warmbrunn said.

“We are frustrated that the tariffs may limit our future choices as the best, or only, choice of manufacturer for many specialized topical products are often outside the US,” Mr Warmbrunn said.

According to the Washington DC-based law firm **Covington & Burling**: “There have been several legal challenges to President Trump’s imposition of tariffs under the International Emergency Economic Powers Act of 1977.”

“Three cases filed in the US Court of International Trade and the US District Court for the District of Columbia have resulted in decisions invalidating the IEEPA tariffs, and those decisions are now on appeal,” Covington & Burling said on its website.

David Langsam
Editor